Brief: AN2 Therapeutics Q1 loss from operations USD 16.039 million
11/05/2023 21:10
May 11 (Reuters) - AN2 Therapeutics Q1 operating expenses USD 16.039 million. * Q1 income from operations USD -16.039 million * Q1 net income USD -15.323 million * Q1 EPS USD -0.79
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview